AI
AVDL

Atria Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Atria Investments’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,841
Closed -$149K – 2016
2025
Q2 		$149K Sell
16,841
-17,758
-51% -$156K ﹤0.01% 1947
2025
Q1 		$271K Buy
34,599
+7,867
+29% +$65.9K ﹤0.01% 1674
2024
Q4 		$281K Sell
26,732
-1,494
-5% -$18.1K ﹤0.01% 1623
2024
Q3 		$370K Sell
28,226
-4,952
-15% -$75.4K ﹤0.01% 1495
2024
Q2 		$466K Buy
+33,178
New +$541K 0.01% 1343

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Atria Investments's AVDL Position: Q3 2025 in Review

Atria Investments sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 16,841 shares — an estimated $149K sold.

Atria Investments first reported a position in AVDL in Q2 2024 and held it in 5 quarters. The position peaked at $466K in Q2 2024. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Atria Investments reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Atria Investments sold 16,841 Avadel Pharmaceuticals shares in Q3 2025, an estimated $149K.
  • Atria Investments first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Atria Investments's Avadel Pharmaceuticals position peaked at $466K in Q2 2024.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Atria Investments's 13F filing for Q3 2025, filed 6 Nov 2025.